U.S. pharmaceutical giant Pfizer has approached British rival AstraZeneca to propose a 60 billion pound takeover, Britain's Sunday Times reported.» Read More
Ads for Pfizer Inc.'s Celebrex arthritis drug are set to splash across U.S. television screens on Monday after more than a two-year hiatus, with an unusual upfront focus on its risks rather than its benefits.
Embargo-gate at the ACC Scientific journals and medical groups employ media embargoes on studies that are to be published or presented. The common practice gives reporters like me a chance to read and digest the information in advance, interview researchers and experts, maybe talk to patients so that when the embargo lifts full and accurate stories will air, run in the papers or cross the wires. It also gives the journals and medical groups a way to manage the news cycle and get more media bang for their publication or conference. Such was supposed to be the case at this week's American College of Cardiology conference in New Orleans.
Stocks ended mixed as the major markets bounced off the day's lows following disappointing monthly housing data. "We may see some weakness, but overall we like the market. I think the direction is going to be higher," said Sebastian Leburn, chief investment officer at Weiss Capital Management, in an interview with CNBC.com.
Merck and Schering-Plough said on Monday they were beginning development of a cholesterol-lowering product that would combine their Zetia drug with Pfizer's Lipitor.
Pfizer's abandoned experimental drug torcetrapib failed to slow clogging of heart arteries even as it boosted "good" cholesterol levels, according to a study presented Monday.
Stocks closed near the unchanged mark as investors pulled money out of the tech sector and moved into energy stocks. "With the recent volatility that we've had, investors are taking a closer look at their portfolios and they're a little more cautious," said Ron Papanek, a strategist with RiskMetrics Group.
The decision bars Teva from launching a competitor drug in the U.S. until December 2015, Pfizer said.
We're gearing up for a busy few days on the beat starting Friday. That's when biotech giant Genentech holds its annual analyst meeting in New York City. We'll be there. Last year the company put out new, boosted financial guidance in the middle of the trading day and it moved the stock. CEO Art Levinson told the crowd of analysts he liked to time it that way so they'll stick around for the whole day.
Last night I debated John Challenger of Challenger, Gray and Christmas, the firm that each year comes out with that March Madness lost wages study.
In a matter of seconds, Cramer lambastes three callers' stocks. Sometimes the truth hurts.
Pfizer said the FDA approved Lipitor for new uses including treating nonfatal heart attacks, fatal and nonfatal strokes, certain types of types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.
What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The House Financial Services Committee Thursday holds a public hearing on the issue and the hue and cry about greed and abuse is bound to bounce off the walls of Congress. The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects.
Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Onyx Pharmaceuticals is up big for the second day in a row. The stock nearly doubled yesterday on astronomical volume of 56,000,000 shares and today as I write this it's up almost 8% with more than 18,000,000 shares changing hands. So, what's up besides the stock?
What many see as outrageous or obscene compensation for chief executive officers is back in the limelight after some high profile pay packages lately. The WEF meeting is tackling the issue by asking basic questions: What’s an appropriate level for top managers? Who defines “appropriate” and how? Should a CEO’s pay be linked to the company’s performance? The contrarian view is that there is little or no direct link between pay and performance and coupling the two might be detrimental because CEOs would cut corners to boost their pay, eroding the company’s long-term prospects. (More)
When Pfizer announced its deeper cost cuts last week, including a total of about 10,000 layoffs, analysts said other big drug companies that had not already started restructuring would use the industry giant as the model. Sure enough, today AstraZeneca said it will get rid of 3,000 employees (5% of its workforce) over the next few years. Also: Gilead shares at record high.
The pharmaceutical company said fourth-quarter net income fell 81%, weighed down by liability and restructuring charges. However, excluding these items, Lilly's profits outpaced analysts' expectations.